ATLANTA, GA - November 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and cancer immunotherapies, announced that its Chairman & CEO, David Dodd, will present at NobleCon21 - the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference. The conference will take place December 2-3, 2025, in Boca Raton, FL.
Dodd's presentation, titled "GeoVax Corporate Update," is scheduled for December 3, 2025, at 3:00 pm ET at the Florida Atlantic University Executive Education Complex. Interested investors and guests can attend at a discounted rate by registering here using the discount code GOVXNOBLECON. A high-definition video webcast of the presentation will be available the following day on the Noble Capital Markets' Conference website and on Channelchek, the investor portal created by Noble. The webcast will be archived for 90 days following the event.
This announcement comes as GeoVax advances its lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. The trials are evaluating the vaccine as a primary vaccine for immunocompromised patients, including those with hematologic cancers, as a booster for patients with chronic lymphocytic leukemia (CLL), and as a more durable booster for healthy individuals who previously received mRNA vaccines. In oncology, GeoVax is evaluating Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
Additionally, GeoVax is developing a vaccine targeting Mpox and smallpox, and based on recent regulatory guidance, the company anticipates progressing directly to a Phase 3 clinical evaluation. GeoVax holds a strong intellectual property portfolio with worldwide rights for its technologies and product candidates. More information about the company's clinical trials and updates can be found on its website: www.geovax.com.
The presentation at NobleCon21 provides an opportunity for GeoVax to update investors on its progress and strategic direction, highlighting its efforts to address unmet medical needs in infectious diseases and oncology. The conference brings together emerging growth companies and investors, offering a platform for networking and discussion of investment opportunities.
